GIVASTOMIG
UNII 8MSM5N7RMK

Substance Identification & Data

This profile provides standardized clinical and technical data for Givastomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8MSM5N7RMK.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2762499-30-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

8MSM5N7RMK

CAS Registry Number

2762499-30-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

GIVASTOMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C180884

National Cancer Institute reference terminology for clinical and research data.

INN ID

12650

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Givastomig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Givastomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Givastomig

Common Names & Synonyms

Fused G1-scFv lambda-heavy chain humanized (1-716) [gamma1 heavy chain anti-CLDN18 humanized (1-450) [VH (Homo sapiens IGHV1-3*01 (85.7%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120)-Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120, CH3 E12, M14, IGHG1v29 CH2 A84.4 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 N84.4>A (300) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)] -15-mer tris(tetraglycyl-seryl) linker (451-465) -scFv lambda-heavy anti-TNFRSF9 humanized, scFv-v2 C120 (VL)-C49 (VH) (466-716) [V-LAMBDA (Homo sapiens IGLV1-47*02 (91.8%) -IGLJ2*01 (90.9%), C120 (568), CDR-IMGT [8.3.11] (491-498.516-518.555-565)) (466-575) -20-mer tetrakis(tetraglycyl-seryl) linker (576-595) -VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (100%), C49 (639), CDR-IMGT [8.8.14] (621-628.646-653.692-705)) (596-716)]]; (223-220')-disulfide with kappa light chain anti-CLDN18 humanized (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (88.1%) -IGKJ2*01 (91.7%) Q120>G (106'), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (159'), V101 (197') (114'-220')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, non-glycosylated

Givastomig [WHO-DD]

Immunoglobulin G1 [300-alanine], anti-(claudin CLDN18.2) (human-Mus musculus γ1-chain) fusion protein with peptide linker ((GGGGS)3) fusion protein with immunoglobulin anti-(tumor necrosis factor receptor TNFRSF9) (human-Mus musculus single-chain variable fragment VL-(GGGGS)4-VH), disulfide with human κ-chain, dimer

Immunoglobulin G1-scFv_L-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, SFTPJ, surfactant associated protein J)isoform 2, extracellular domain 1 (EC1)], anti-[Homo sapiens TNFRSF9 (TNF receptor superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], humanized monoclonal antibody, bispecific, agonist

givastomig [INN]

External Clinical & Regulatory Resources

Previous UNII8MSF4B5XHZ

Next UNII8MSY49469G